LRP6 and neoplasm: For example, pharmacological blockade of WNT signaling with LGK974, which inhibits WNT ligand secretion through the acyltransferase porcupine, or with an antibody against the WNT receptor LRP6 leads to a reduction in the number of DTP cells and a delay of tumor relapse upon drug withdrawal (51, 52, 76).